mcna priority review, afatinib application accepted, asco nsclc guidelines, and more
Published 9 years ago • 113 plays • Length 6:50Download video MP4
Download video MP3
Similar videos
-
9:27
fda approvals in rcc and cml, priority review designations in nsclc and rcc, and more
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
0:58
the activity of afatinib in lung cancer
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
8:47
study of 693 nsclc patients treated with afatinib
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
1:35
dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer
-
6:46
selecting a first-line egfr inhibitor in nsclc
-
0:17
afatinib inhibits egfr receptor activation
-
0:51
dr. west discusses afatinib and cetuximab combination in nsclc
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
1:32
real-world comparison assesses mobocertinib in nsclc with egfr exon 20
-
2:34
giotag: real world data on first-line afatinib followed by osimertinb
-
4:09
frontline afatinib in egfr-mutant nsclc
-
0:44
afatinib
-
3:32
rapid recommendation update from asco for stage ib-iiia nsclc
-
1:35
afatinib for advanced egfrm-positive nsclc
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc